IGF1R-targeted delivery of a bridged nucleic acid oligonucleotide-peptide conjugate for microRNA-21 inhibition in triple-negative breast cancer
NAR Cancer · 2025
DOI: 10.1093/narcan/zcaf053 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, 2025. Verfasst von Yuanyuan Jin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Bound Therapeutics LLC, Philadelphia, PA 19104, United States. Hauptthemen laut MEDLINE: MicroRNAs, Triple Negative Breast Neoplasms, Receptor, IGF Type 1, Oligonucleotides. Die Arbeit nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH, Bound Therapeutics LLC.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC), defined by the absence of ER, PR, and Her2, impacts over 46 000 U.S. women annually, disproportionately affecting minority ethnic groups and individuals with BRCA mutations. Despite advancements such as PARP inhibitors, TNBC remains highly aggressive, with frequent recurrences and a 50% mortality rate within four years, underscoring the urgent need for more effective targeted therapies. MicroRNAs (miRNAs) represent a novel therapeutic approach. In TNBC, overexpressed miR-21 drives tumor progression, immune evasion, treatment resistance, and metastasis. Targeted miR-21 inhibition could curb these effects while minimizing harm to normal cells. We developed a peptide-conjugated miR-21 inhibitor targeting TNBC cells via the overexpressed IGF1 receptor (IGF1R), associated with poor prognosis. Using aminomethyl-bridged nucleic acid (BNA) chemistry, a serum-stable anti-miR-21 RNA analog was designed and tested for its effects on TNBC cell proliferation, apoptosis, tumor suppressor expression, and immune checkpoint regulation. Conjugation to an IGF1 peptide analog improved delivery, demonstrating tumor-specific biodistribution, efficacy, and safety in TNBC-bearing mice. The miR-21 inhibitor-peptide conjugate reduced proliferation, induced apoptosis, elevated tumor suppressors, and suppressed immune checkpoints in TNBC cell lines. In vivo, it concentrated in tumors, inhibited tumor growth, and showed no detectable liver or kidney toxicity at the tested dose, supporting therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Bound Therapeutics LLC, Philadelphia, PA 19104, United States.
- Center for Cellular Immunotherapy, University of Pennsylvania, Philadelphia, PA 19104, United States.
ORCID-Profile: Eric Wickstrom
Förderung
- NCI NIH HHS
- NIH
- Bound Therapeutics LLC
Zitieren
APA
Jin, Y., Desai, V. S., Mazzaroth, J. D., & Wickstrom, E. (2025). IGF1R-targeted delivery of a bridged nucleic acid oligonucleotide-peptide conjugate for microRNA-21 inhibition in triple-negative breast cancer. NAR Cancer. https://doi.org/10.1093/narcan/zcaf053
Vancouver
Jin Y, Desai VS, Mazzaroth JD, Wickstrom E. IGF1R-targeted delivery of a bridged nucleic acid oligonucleotide-peptide conjugate for microRNA-21 inhibition in triple-negative breast cancer. NAR Cancer. 2025. doi:10.1093/narcan/zcaf053
BibTeX
@article{Jin2025,
author = {Jin, Yuanyuan and Desai, Vilas S and Mazzaroth, Jason D and Wickstrom, Eric},
title = {IGF1R-targeted delivery of a bridged nucleic acid oligonucleotide-peptide conjugate for microRNA-21 inhibition in triple-negative breast cancer},
journal = {NAR Cancer},
year = {2025},
doi = {10.1093/narcan/zcaf053}
}
EUVIMED